IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
Ocular pain is a $10+ billion global market with significant unmet medical need. IACTA and Pharmaleads are teaming up to accelerate global development of DENKIs, leveraging expertise and resources of both companies.
Strategic collaboration and licensing agreement to allow for co-development leveraging IACTA formulation and clinical expertise and TALLC’s SmartCelle™ delivery technology Collaboration to expand IACTA’s diverse ophthalmology pipeline Guaynabo,
Ocular Pain, a $10+ billion global market, with significant unmet medical need License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, Calif.,
By Jessie Yount - Featured on ocbj.com CLINICAL TRIALS IACTA Pharmaceuticals Inc. in Irvine nabbed a licensing agreement with Zhaoke Ophthamology Pharmaceutical to co-develop and commercialize two drug candidates in
By David Ho and Elise Mak - Featured on BioWorld.com HONG KONG - California-based Iacta Pharmaceuticals Inc. and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical Ltd. have inked a definitive license agreement
IRVINE, Calif. and HONG KONG -- IACTA Pharmaceuticals, Inc. ("IACTA" or the "Company") and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited ("ZKO"), a leading Hong Kong-based pharmaceutical company, today announces they